Loading
A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended.
ESSA Pharma terminated the phase 2 of masofaniten + enzalutamide in mCRPC (2024) after a futility analysis on PSA90; the company later discontinued development (2025). The EXTRA-PC investigator trial in mHSPC closed early. AR-NTD inhibition remains unproven clinically despite compelling biology (AR-V7).
Binds the disordered N-terminal domain of AR, intended to inhibit full-length and splice-variant AR. Connects to Androgen receptor.
1.Masofaniten acts on Androgen receptor, the hormone receptor or the enzyme that makes the hormone.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Masofaniten" OR ABSTRACT:"Masofaniten" OR TITLE:"EPI-7386" OR ABSTRACT:"EPI-7386") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Masofaniten, not a curated reading list.
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
Shares Androgen receptor, Prostate cancer.
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
Shares Androgen receptor, Prostate cancer.
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
Shares Androgen receptor, Prostate cancer.